SEAGULL HEALTH
Your health,We care!
Its core advantages are potent ROS1 inhibition, high intracranial activity, outstanding anti-resistance efficacy, superior safety profile, and high accessibility.
AuthenticGuaranteeFast DeliveryPrivacy On December 20, 2024, taletrectinib was approved by the National Medical
Products Administration (NMPA) of China for the treatment of adult patients with
ROS1‑positive locally advanced or metastatic non‑small cell lung cancer (NSCLC)
who have progressed following treatment with a ROS1 tyrosine kinase inhibitor
(TKI).
On January 2, 2025, an additional indication was approved for taletrectinib,
for the treatment of adult patients with ROS1‑positive locally advanced or
metastatic NSCLC who are treatment‑naïve to ROS1‑TKIs.
On January 1, 2026, taletrectinib was included in the 2025 edition of the
National Reimbursement Drug List (NRDL) of China.
On June 11, 2025, taletrectinib was approved in the United States for the
treatment of adult patients with locally advanced or metastatic ROS1‑positive
NSCLC, regardless of prior TKI treatment history.
On January 6, 2025, Nuvalent, Inc. announced that its independently developed taletrectinib has been approved by the National Medical Products Adminis···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 102
On December 20, 2024, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Talrectinib Adipate Capsul···【Read More】
Update: 30 Jan,2026Source: Haiou HealthViews: 117
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
